©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
Bovine Oxytocin Transgenes in Mice
HYPOTHALAMIC EXPRESSION, PHYSIOLOGICAL REGULATION, AND INTERACTIONS WITH THE VASOPRESSIN GENE (*)

(Received for publication, June 19, 1995; and in revised form, August 30, 1995)

Mei-Yin Ho David A. Carter (§) Hwee-Luan Ang (¶) David Murphy (**)

From the Neuropeptide Laboratory, Institute of Molecular and Cell Biology, Singapore 0511, Republic of Singapore

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

To gain insights into the molecular mechanisms that restrict the expression of the oxytocin gene to anatomically defined groups of neurons in the hypothalamus, we generated transgenic mice bearing bovine oxytocin genomic fragments. Appropriate neuron-specific and physiological regulation was observed in mice bearing transgene bOT3.5, which consists of the oxytocin structural gene flanked by 0.6 kilobase pair (kbp) of upstream and 1.9 kbp of downstream sequences. bOT3.5 is expressed in oxytocin magnocellular neurons in the mouse supraoptic nucleus and paraventricular nucleus, but transgene RNAs are excluded from vasopressin neurons. Replacement of the drinking diet of the transgenic mice with 2% (w/v) NaCl for 7 days significantly increased the abundance of bovine oxytocin transcripts in the supraoptic nucleus, but not in the paraventricular nucleus, in parallel with the endogenous mouse oxytocin RNA. Surprisingly, mimicry of the endogenous oxytocin gene expression pattern was lost with larger transgenes. Addition of 0.7 kbp of contiguous downstream sequences (transgene bOT) or linkage to the bovine vasopressin gene (transgene VP-B/bOT3.5) repressed hypothalamic expression. No mice were derived bearing transgene bOT6.4, which consists of the oxytocin structural gene flanked by 3 kbp of upstream and 2.6 kbp of downstream sequences, suggesting that the presence of this DNA is detrimental to normal embryonic development. These data suggest that while bOT3.5 contains sufficient cis-acting sequences to mediate expression to particular subsets of hypothalamic neurons, the overall regulation of the oxytocin gene is governed by multiple interacting enhancers and repressors.


INTRODUCTION

Ever since pioneering studies demonstrated that the posterior pituitary contains activities that stimulate uterine contraction (1) and milk ejection(2) , the oxytocin (OT) (^1)system has been a favorite model for the study of the regulation and function of an identified class of central peptidergic neurons. OT is synthesized as a prepropeptide in the cell bodies of anatomically defined groups (nuclei) of hypothalamic magnocellular neurons. This precursor is subject to cleavage and other modifications as it is transported down the axon to terminals located in the posterior pituitary(3) . The mature peptide products (the nonapeptide OT and a putative carrier molecule termed neurophysin) are stored until neural inputs governed by physiological stimuli elicit their release into the general circulation (4) . Through an interaction with OT receptors located in the uterus and mammary gland, OT stimulates smooth muscle contraction, leading to parturition or milk ejection.

The single-copy structural gene encoding the OT prepropeptide consists of three exons and encompasses <1 kbp(5) . The OT gene is highly homologous at both the structural and sequence level to the gene encoding the related neuropeptide vasopressin (VP). In mammals, the two genes are separated by a short intergenic region of 11 kbp in the rat (5) and of 3 kbp in the mouse (6) and are transcribed toward each other from opposite strands of the DNA duplex. An attractive feature of the OT system is that, within the hypothalamus, the expression of the OT gene is confined to anatomically defined groups of magnocellular neurons in the supraoptic nucleus (SON) and in the paraventricular nucleus (PVN). VP is also expressed in hypothalamic magnocellular neurons, but VP and OT are rarely found in the same cell(7, 8, 9) . The OT gene is also expressed in a number of peripheral tissues(10) .

Studies on the physiological regulation of OT gene expression in the hypothalamus have benefited from the exploitation of well established paradigms for the modulation of the activity of OT neurons. These experiments have revealed that OT gene expression in magnocellular cells is increased in response to functional demand. Thus, during pregnancy and lactation, when pituitary stores of OT are depleted, the abundance of the OT mRNA in the hypothalamus increases(11) . Surprisingly, despite being expressed in distinct magnocellular neurons, the VP mRNA also increases in abundance during pregnancy and lactation(11) . Conversely, osmotic stimuli (such as salt loading) that result in functional demand for VP and an increase in VP gene transcription (12, 13) and VP mRNA abundance (14, 15, 16, 17) also result in similar changes in OT expression(16, 18) .

Little is known about the regulation of OT gene expression in the hypothalamus in terms of either the synaptic regulation of phenotype and physiological status or their mediation by second messengers, transcription factors, and cognate OT gene cis-acting elements. In vitro studies have described cis-elements in the OT gene promoter that are able to mediate transcriptional regulation, but the physiological relevance of these findings remains to be determined. For example, Richard and Zingg (19) have shown that the human OT promoter is able to direct the high level expression of a reporter in the mouse neuroblastoma cell line Neuro 2A. The sequences mediating this effect have been shown to consist of at least three cooperating elements located within the 50 base pairs upstream of the mRNA cap site. Both rat and human OT promoters contain direct and inverted repeats of an AGGTCA nuclear hormone receptor-binding site. Transfections into heterologous cultured cells have shown that these sequences can mediate transcriptional up-regulation of the OT promoter in response to the ligand-dependent binding of the estrogen(20, 21) , thyroid hormone(22) , and retinoic acid (23) receptors. Although the presence of these receptors in oxytocinergic neurons has not been demonstrated (24) , the finding that OT gene expression in the rat uterus (25) is estrogen-responsive (26, 27) may provide a physiological context within which these elements function. The bovine OT promoter is not responsive to estrogen(28) .

To define broad regulatory regions required for appropriate expression, we have generated transgenic mice bearing the bovine OT gene. Here, we describe a bovine OT transgene that is expressed in a cell type-specific manner in the mouse hypothalamus, within which it is subject to physiological regulation. The hypothalamic expression of this transgene is repressed by downstream sequences and by sequences in the VP gene.


MATERIALS AND METHODS

Transgene Construction

All transgenes were derived from bovine genomic sequences isolated and kindly donated by Siegfried Ruppert and colleagues(29) . Fig. 1shows the extent of the transgenes described in this study. bOT6.4 is a 6.4-kbp transgene fragment consisting of the OT structural gene flanked by 3 kbp of upstream (defined by a PstI site) and 2.5 kbp of downstream (defined by an EcoRI site) sequences. bOT, a 4.2-kbp EcoRI OT gene fragment, consists of the structural gene flanked by 0.6 kbp of upstream and 2.5 kbp of downstream sequences(31) . bOT3.5 is a 3.5-kbp transgene consisting of the OT structural gene flanked by 0.6 kbp of upstream (defined by an EcoRI site) and 1.8 kbp of downstream (defined by an XbaI site) sequences. VP-B is a 3.45-kbp VP transgene fragment consisting of the structural gene flanked by 1.25 kbp of upstream (defined by an HhaI site converted to a SalI site) and 0.2 kbp of downstream (defined by an XbaI site) sequences(31) . bOT3.5 and VP-B were joined at their respective downstream XbaI sites to generate transgene VP-B/bOT3.5 (see Fig. 1). The VP and OT genes in VP-B/bOT3.5 are thus arranged in a 3` to 3` transcriptional orientation. Fragments were freed from vector sequences prior to their use as transgenes.


Figure 1: Structures of bovine VP and OT transgenes. Shown are the structures of the bovine VP and OT transgenes described in this study and their relationship to the rat VP-OT locus (5) and to previously described rat (37) and bovine (30, 31) transgenes. The horizontal arrows indicate the direction of transcription. Shaded boxes represent exons. Rat transgenes are shown above the locus map, and bovine transgenes are shown below. Expression patterns for either VP (left side) or OT (right side) are described. HYP, hypothalamus; TEST, testis.



Animals

Animals were cared for in accord with National Institutes of Health guidelines. Transgenic mice were generated by microinjecting fertilized one-cell eggs obtained from crosses between F1 (CBA/J times C57BL/10) mice. All procedures have been described(32) . Only Southern blot positive heterozygous transgenic animals were used for expression analysis. Salt loading of mice involved the replacement of the normal tap water drinking diet with 2% (w/v) NaCl in tap water for 7 days.

Expression Analysis

Except for the ovary and uterus when virgin females were used, male mice were used throughout. The extraction of RNA using guanidinium isothiocyanate and its analysis by Northern blotting have been described(32) . In one experiment (shown in Fig. 2B and Table 2, Experiment 2), RNA was extracted using Trizol (Life Technologies Inc.). Northern blots were controlled for equal loading and even transfer in two ways. First, following transfer, the ethidium bromide-stained filter was viewed and photographed under ultraviolet light. Second, filters were routinely reprobed with oligonucleotides corresponding to the mRNAs encoding either glyceraldehyde-6-phosphate dehydrogenase or alpha-tubulin. The abundance of these RNAs does not change in the hypothalamus following physiological stimulation and thus can be used as quantitation standards. Note that alpha-tubulin and glyceraldehyde-6-phosphate dehydrogenase RNAs are expressed at different levels in different tissues and that the relative pattern of expression observed is consistent between animals. The oligonucleotide probes specific for the rodent and bovine OT and VP RNAs have been described(30, 31) . Northern blot autoradiograms from salt loading experiments were subjected to quantitative analysis. Linear range exposures were scanned by laser densitometry (Pharmacia Biotech Ultroscan or Millipore Bio Image Visage 110), and the levels of bovine OT, mouse OT, or mouse VP RNA were determined relative to the level of the alpha-tubulin or glyceraldehyde-6-phosphate dehydrogenase RNAs and are expressed as a percentage of the mean of the control groups (±S.E.). Statistical significance was determined using Student's t test. In situ hybridization of radiolabeled oligonucleotides to RNA in brain sections has been described(31, 32) . In situ slides from salt loading experiments were subjected to quantitation. 10-µm coronal sections were cut through the entire hypothalamus of control or salt-loaded mice. Every fourth slide was probed with the bovine-specific oligonucleotide OT probe, while the adjacent slide was probed with the mouse-specific (rodent) oligonucleotide OT probe. Images of linear range exposures were captured using a Nikon Microphot FXA microscope equipped with a linear video camera (Eastman Kodak Megaplus Model 1.4). Captured images were analyzed using the Voxelview/ULTRA 2.1 software (Vital Images Inc., Fairfield, IA) on a Silicon Graphics Unix workstation. The number of expressing cells and the mean of the summated hypothalamic expression level were expressed as a percentage of the mean of the control groups (±S.E.). Statistical significance was determined using Student's t test. In some experiments, sections were simultaneously hybridized with radiolabeled and digoxygenin-labeled probes to reveal the localization of two different RNA species(33) .


Figure 2: Expression and physiological regulation of bovine OT RNA in the hypothalamus of bOT3.5. A, Northern analysis of hypothalamic RNA from the following: lane 1, bOT2 (30 µg)(30) ; lane 2, bOT3.5 line 1 (30 µg); lane 3, VP-B/bOT3.5 line 3 (30 µg); lane W, wild-type mouse (40 µg); lane B, wild-type cattle (20 µg). B, Northern analysis of hypothalamic RNA (extracted using Trizol) from hypothalami (six/group) of control (C1-C3; 50 µg/lane) and salt-loaded (S1-S3; 50 µg/lane) bOT3.5 line 1 and from wild-type mouse (50 µg) and wild-type cattle (50 µg). RNAs were subjected to Northern blotting and probed sequentially with oligonucleotides corresponding to bovine OT RNA (BOT), rodent OTRNA (ROT), rodent VPRNA (RVP), and glyceraldehyde-6-phosphate dehydrogenase RNA (GAPDH). Note that the rodent OT probe fails to detect the bovine OT transcript in the cattle hypothalamus, while the bovine OT probe does not hybridize to the mouse OT RNA in the wild-type mouse hypothalamus.






RESULTS

Generation of Mice Bearing Bovine OT Transgenes

We have previously shown (30) that bOT, a 4.2-kbp transgene consisting of the OT structural gene flanked by 0.6 kbp of upstream and 2.6 kbp of downstream sequences (Fig. 1), is expressed in testicular Sertoli cells and in the lung. No expression of bOT was detected in the hypothalamus (Fig. 2A). To identify sequences that are able to direct transgene expression to central and peripheral sites, we have introduced bovine OT transgenes into mice that are both larger and smaller than bOT. bOT6.4 is the same as bOT, except that it has a total of 3.0 kbp of upstream sequence of the structural gene (Fig. 1). bOT3.5 is the same as bOT, except that it lacks 0.7 kbp of distal downstream sequence (Fig. 1). We have also investigated possible regulatory interactions between the VP and OT genes by introducing transgene VP-B/bOT3.5 into mice (Fig. 1). Fertilized one-cell mouse eggs were injected with the three transgene fragments (Table 1). Transgenes bOT3.5 and VP-B/bOT3.5 yielded transgenic mice at a high efficiency. However, despite injecting a large number of fertilized one-cell mouse eggs with construct bOT6.4, no transgenic animals were identified among the resulting pups (Table 1).



Expression of Bovine OT Transgenes in Mice

Northern analysis demonstrated that transgene bOT3.5, like bOT, was expressed in the testis and lung (Fig. 3). Surprisingly, and unlike bOT, expression of bOT3.5 was also found in the hypothalamus (Fig. 2A and Fig. 3). Within the hypothalamus, in situ hybridization analysis revealed that transgene expression was confined to magnocellular neurons of the PVN and SON (Fig. 4). Neither the endogenous mouse OT RNA nor the transgene RNA was detected in the SCN (data not shown). As in the rat(7) , the endogenous mouse VP and OT genes are expressed in mutually exclusive sets of magnocellular neurons (Fig. 5A). Similarly, bOT3.5 expression was found in neurons expressing the endogenous OT RNA (Fig. 5B), but was generally excluded from neurons expressing the endogenous VP RNA (Fig. 5C). However, as in the rat(8, 9) , a small number of neurons expressing the mouse VP RNA also showed expression of the mouse OT RNA and the bOT3.5 transgene RNA.


Figure 3: Expression of bovine OT RNA in transgenic mice bearing the bOT3.5 transgene. Total RNA was extracted from tissues from two independently derived transgenic mouse lines (lines 2 and 4), and 50 µg was analyzed by Northern blotting(31) . For line 2, the following tissues were examined: BR, brain minus hypothalamus; P, pituitary gland; Hy, hypothalamus; Lv, liver; S, spleen; AD, adrenal gland; K, kidney; T, testis; L, lung; Th, thymus; Ht, heart; Ov, ovary; Ut, uterus; and BH, bovine hypothalamus (positive control). For line 4, the following tissues were examined: St, striatum; MO, medulla oblongata and pons; MB, midbrain; Cb, cerebellum; C, cortex; H, hippocampus; AP, anterior pituitary gland; N, neurointermediate lobe of the pituitary gland; Hy, hypothalamus; Lv, liver; S, spleen; P, pancreas; AD, adrenal gland; K, kidney; T, testis; L, lung; Th, thymus; Ht, heart; Ov, ovary; Ut, uterus; and BH, bovine hypothalamus (positive control). Filters were probed first with an oligonucleotide specific for the bovine OT RNA (BOT) and then with an oligonucleotide corresponding to the rat alpha-tubulin RNA (TUB) as a control for intact total RNA and even transfer. Note that alpha-tubulin RNA is expressed at different levels in different tissues, but the relative pattern of expression observed is consistent between animals. Four independently derived transgenic lines were examined. Representative Northern analyses from two lines (lines 2 and 4) are shown. Line 3 showed no expression of the transgene (data not shown). Expression in the testis, lung, and hypothalamus was seen in each of the three remaining lines. Line 1 also showed some expression in the midbrain, cortex, kidney, and liver (data not shown). Bovine OT RNAs in different tissues do not migrate at the same rate due to poly(A) tail length variations(40) .




Figure 4: Expression of the endogenous OT gene and of the bOT3.5 transgene in the murine hypothalamus is confined to the SON and PVN. Coronal brain sections from transgene bOT3.5 line 1 (BOT3.5) and wild-type (WT) mice were probed with labeled oligonucleotides corresponding to the rodent (ROT) or bovine (BOT) OT RNAs. Representative sections are shown in the vicinity of the PVN and SON. Note that the bovine OT probe does not give any signal in the wild-type mouse hypothalamus.




Figure 5: The OT and VP genes are expressed in mutually exclusive magnocellular neurons in the SON and PVN of the mouse, and the bOT3.5 transgene is expressed only in oxytocinergic neurons. Coronal brain sections from control (C) or salt-loaded (S) transgene bOT3.5 line 1 (BOT3.5) and wild-type (WT) mice were probed simultaneously with a S-labeled oligonucleotide (indicated by an asterisk) and a digoxygenin-labeled oligonucleotide. The oligonucleotides used were rodent OT (ROT), bovine OT (BOT), and rodent VP (RVP). Representative areas of the SON and PVN are shown. The digoxygenin probe is revealed by brown coloration of the cell body cytoplasm (in focus in the upper panel). The radioactive probe is revealed by grains that are in a different focal plane to the nonradioactive probe (shown in focus in the lower panel). A, rodent OT and rodent VP are present in mutually exclusive sets of magnocellular neurons. B, bovine OT colocalizes with rodent OT. C, bovine OT is excluded from neurons expressing rodent VP.



We have previously shown that transgene VP-B is expressed throughout the nervous system(31) . However, when linked to bOT3.5 in transgene VP-B/bOT3.5, no expression of the VP component was detected (data not shown), and transcripts from the OT component were seen in the testis and lung (Fig. 6), but not in the hypothalamus (Fig. 2A and Fig. 6).


Figure 6: Expression of bovine OT RNA in transgenic mice bearing the VP-B/bOT3.5 transgene. Total RNA was extracted from tissues from three independently derived transgenic mouse lines (lines 1-3), and 50 µg was analyzed by Northern blotting(31) . For lines 1 and 2, the following tissues were examined: BR, brain; Lv, liver; S, spleen; AD, adrenal gland; K, kidney; T, testis; L, lung; Th, thymus; Ht, heart; Ov, ovary; Ut, uterus; and BH, bovine hypothalamus (positive control). For line 3, the following tissues were examined: BR, brain minus hypothalamus; P, pituitary gland; Hy, hypothalamus; Lv, liver; S, spleen; K, kidney; T, testis; L, lung; Th, thymus; Ht, heart; Ov, ovary; Ut, uterus; and BH, bovine hypothalamus (positive control). Filters were probed first with an oligonucleotide specific for the bovine OT RNA (BOT) and then with an oligonucleotide corresponding to the rat alpha-tubulin RNA (TUB) as a control for intact total RNA and even transfer. Note that alpha-tubulin RNA is expressed at different levels in different tissues, but the relative pattern of expression observed is consistent between animals. Four independently derived transgenic lines were examined. Representative Northern analyses from three lines (lines 1-3) are shown. Expression in the testis and lung was seen in each line. Bovine OT RNAs in different tissues do not migrate at the same rate due to poly(A) tail length variations(40) .



Physiological Regulation of Bovine OT Transgene Expression in Mice

We asked if expression of bOT3.5 in the hypothalamus is regulated by a stimulus that modulates the expression of the endogenous OT gene. Replacement of the drinking diet of mice with 2% (w/v) NaCl for 7 days increased the hypothalamic level of the endogenous mouse OT and VP RNAs, as assayed by Northern blotting (Fig. 2B and Table 2). However, Northern blotting revealed no significant change in the level of the transgene RNA (Fig. 2B and Table 2). Quantitative in situ hybridization analysis (Fig. 7) revealed that the transgene RNA level was modulated in only one group of magnocellular OT neurons; an effect was masked from detection using Northern blotting. Thus, while salt loading had no significant effect on the levels of either the endogenous or transgene OT RNAs in the PVN (Fig. 7, B and C), both were significantly elevated in the SON (Fig. 7, A and B). Salt loading had no effect on the number of cells expressing either transgene or endogenous RNAs in either the SON or PVN (data not shown). The expression of the endogenous murine OT RNA and the transgene RNA was generally excluded from VP neurons in salt-loaded animals (Fig. 5).


Figure 7: Salt loading increases the abundance of mouse and bovine RNAs in the SON of bOT3.5 transgenic mice, but has no effect on the level of these transcripts in the PVN. A, serial sections through the SON of control (C) or salt-loaded (S) bOT3.5 line 1 probed with oligonucleotides corresponding to the rodent (ROT) or bovine (BOT) OT RNA. B, Voxelview analysis of the level of expression of RNAs detected by the bovine OT probe (BOT) and the rodent OT probe (ROT) in the PVN and SON in control (open bars) and salt-loaded (closed bars) bOT3.5 line 1 transgenic mice. C, serial sections through the PVN of control or salt-loaded bOT3.5 line 1 probed with oligonucleotides corresponding to the rodent (ROT) or bovine (BOT) OT RNA. The base of the brain (ventral surface) is to the right. Serial sections run rostral to caudal from the left to the right.




DISCUSSION

While the molecular mechanisms underlying the cell-specific and physiological regulation of the OT gene are the subject of much interest(34) , mechanistic understanding has lagged behind descriptive studies because of the lack of appropriate cell culture systems. To circumvent this obstacle(35) , we have applied transgenesis to the OT system.

We have previously described the expression in mice of the 4.2-kbp transgene bOT(30, 36) . bOT RNAs were detected in the testis and lung, but not in the hypothalamus. Initially, we thought that bOT must be missing elements crucial for expression in OT neurons. However, we now show that bOT contains too much sequence information, rather than too little. Surprisingly, bOT3.5, which differs from bOT only in that it lacks 0.7 kbp of distal downstream flanking sequence, is expressed consistently in the hypothalamus, within which transgene expression is confined to magnocellular cells in the PVN and SON that also express the endogenous mouse OT gene. Transgene RNAs, like the endogenous OT transcripts, are excluded from neurons expressing mouse VP RNAs. We suggest that the downstream sequences present in bOT (but absent from bOT3.5) contain one or more repressor elements that prevent the detectable expression of the former transgene in hypothalamic oxytocinergic neurons. It follows that in the normal genomic context of the OT gene, the activity of the putative repressors must be repressed or overridden.

We were unable to generate any transgenic mice bearing construct bOT6.4 (Table 1). bOT6.4 differed from bOT only in that the sequence upstream of the start of transcription consisted of 3.0 kbp, rather than the 0.6 kbp found in the latter transgene. Young et al.(37) have described a similar situation with a rat OT transgene. No transgenic mice were represented in the pups resulting from the injection of fertilized one-cell mouse eggs with ROT1.63, which consisted of the entire rat OT structural gene flanked by 0.36 kbp of upstream and 0.4 kbp of downstream sequences (Fig. 1). Both rat and cattle OT genes contain sequences that are detrimental to normal development. In the bovine gene, these sequences must reside in the 2.4 kbp of distal upstream sequences, present in bOT6.4, but absent in bOT. Presumably, ectopic OT expression, mediated by these sequences at an inappropriate time, is incompatible with embryogenesis. In the context of the normal OT gene, this toxic effect must be repressed.

Because of the close linkage between the VP and OT genes, it has been suggested that interactions between the two transcription units may be important in locus control. Here, we show that the bovine VP and OT genes can affect the expression of each other. The VP-B/bOT3.5 transgene consists of the VP-B and bOT3.5 constructs linked 3` to 3` (Fig. 1). We have previously shown that VP-B, consisting of the bovine VP structural gene flanked by 1.25 kbp of upstream and 0.2 kbp of downstream sequences, is expressed in all neuronal tissues examined (31) . As described above, bOT3.5 is expressed in OT neurons, testis, and lung. In mice containing the VP-B/bOT3.5 transgene, expression of the VP component could not be detected in any central or peripheral tissue, while expression of transgene OT RNA was seen only in the testis and lung. Thus, sequences within the OT component of the transgene prevented expression of the VP portion in neuronal cells, while sequences within VP-B repressed the hypothalamic expression of bOT3.5. Support for the concept of cross-talk between the VP and OT genes has also come from the experiments of Young et al.(37) . These authors described mice bearing a minilocus transgene (V2) consisting of construct ROT1.63 (see above and Fig. 1) linked to sequences from the rat VP gene (transgene RVP3.55) (Fig. 1). No transgenic mice were derived from the microinjection of fertilized one-cell mouse eggs with ROT1.63 (see above). On its own, RVP3.55, consisting of the structural gene flanked by 1.4 kbp of upstream and 0.4 kbp of downstream sequences (Fig. 1), was not expressed. (^2)In the V2 minilocus transgene, the two genes were arranged in the opposite transcriptional orientation (VP 3` to OT 5`) to the native genes (VP 3` to OT 3`). The VP component of the V2 minilocus was again silent. However, the OT transcription unit present in V2 was expressed in oxytocinergic magnocellular neurons(37, 38, 39) . Thus, elements within the VP component must repress the deleterious effects of the OT portion, allowing transgenic mice to be generated. Thus, the close linkage of the VP and OT genes may be important for overall locus control, perhaps by coordinating responses of the two genes to developmental or regulatory cues. However, it should be noted that our data also suggest that there is redundancy in the regulatory elements contained within the two transcription units as the bOT3.5 transgene, consisting only of OT gene sequences and proximal flanks, is expressed autonomously in oxytocinergic neurons. Similarly, we have described bovine VP transgenes that are properly regulated in the hypothalamus(31) .

Physiological stimuli are known to affect the pattern of OT gene expression in the hypothalamus, and we asked if these same stimuli altered the expression of the bOT3.5 transgene. We have shown that the level of bovine OT RNA increased in the hypothalamus during salt loading, in parallel with the endogenous mouse OT RNA. Thus, the sequences mediating the physiological up-regulation of bovine OT gene expression reside within the confines of the bOT3.5 transgene. Interestingly, while salt loading resulted in a significant increase in both the endogenous mouse and transgenic bovine OT RNAs in the SON, no change in either RNA could be seen in the PVN. These data suggest that in the mouse, unlike in the rat(16) , the two nuclei respond differentially to an osmotic stimulus.

In summary, transgene bOT3.5 contains sufficient sequence information to direct expression to murine oxytocinergic magnocellular neurons, within which it is subject to physiological regulation. However, this expression pattern is not found when the same bOT3.5 sequences are linked either to the contiguous 0.7 kbp of downstream sequence (in bOT) or to the VP gene (in VP-B/bOT3.5), which is closely linked to the OT gene in mammals(5, 6) . The expression patterns seen with bovine VP (31) and OT ( (30) and this report) transgenes in mice suggest that the cell type-specific expression of these genes is mediated by interactions between multiple enhancers and repressors located in both transcription units.


FOOTNOTES

*
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
Present address: Physiology Unit, School of Molecular and Medical Biosciences, University of Wales College of Cardiff, Cardiff CF1 1SS Wales, United Kingdom.

Present address: La Jolla Cancer Research Foundation, Cancer Research Center, 10901 North Torrey Pines Rd., La Jolla, CA 92037.

**
To whom correspondence should be addressed. Tel. and Fax: 65-777-5489; mcbdavid@leonis.nus.sg.

(^1)
The abbreviations used are: OT, oxytocin; kbp, kilobase pair(s); SON, supraoptic nucleus; PVN, paraventricular nucleus; VP, vasopressin.

(^2)
W. S. Young III, personal communication.


ACKNOWLEDGEMENTS

Sandra Jones and the staff of the Institute of Molecular and Cell Biology animal holding unit are thanked for expert animal care.


REFERENCES

  1. Dale, H. H. (1906) J. Physiol. (Lond.) 34, 165-206
  2. Ott, I., and Scott, J. C. (1911) Proc. Soc. Exp. Biol. Med. 8, 48-49
  3. Brownstein, M., Russel, J., and Gainer, H. (1980) Science 207, 373-387 [Medline] [Order article via Infotrieve]
  4. Renaud, L. P., and Bourque, C. W. (1991) Prog. Neurobiol. 36, 131-169 [CrossRef][Medline] [Order article via Infotrieve]
  5. Schmitz, E., Mohr, E., and Richter, D. (1991) DNA Cell Biol. 10, 81-91 [Medline] [Order article via Infotrieve]
  6. Hara, Y., Battey, J., and Gainer, H. (1990) Mol. Brain Res. 8, 319-324 [Medline] [Order article via Infotrieve]
  7. Mohr, E., Bahnsen, U., Kiessling, C., and Richter, D. (1988) FEBS Lett. 242, 144-148 [CrossRef][Medline] [Order article via Infotrieve]
  8. Kiyama, H., and Emson, P. C. (1990) J. Neuroendocrinol. 2, 257-260
  9. Mezey, E., and Kiss, J. Z. (1991) Endocrinology 129, 1814-1820 [Abstract]
  10. Murphy, D., Funkhouser, J., Ang, H.-L., Foo, N.-C., and Carter, D. A. (1993) Ann. N. Y. Acad. Sci. 689, 91-106 [Medline] [Order article via Infotrieve]
  11. van Tol, H. H. M., Bolwerk, E. L. M., Liu, B., and Burbach, J. P. H. (1988) Endocrinology 122, 945-951 [Abstract]
  12. Murphy, D., and Carter, D. A. (1990) Mol. Endocrinol. 4, 1051-1059 [Abstract]
  13. Herman, J. P., Schafer, M. K.-H., Watson, S. J., and Sherman, T. G. (1991) Mol. Endocrinol. 5, 1447-1456 [Abstract]
  14. Burbach, J. P. H., De Hoop, M. J., Schmale, H., Richter, D., De Kloet, E. R., Ten Haaf, J. A., and De Wied, D. (1984) Neuroendocrinology 39, 582-584 [Medline] [Order article via Infotrieve]
  15. Zingg, H. H., Lefebvre, D., and Almazan, G. (1986) J. Biol. Chem. 261, 12956-12959 [Abstract/Free Full Text]
  16. Lightman, S. L., and Young, W. S., III (1987) J. Physiol. (Lond.) 394, 23-39 [Abstract]
  17. Sherman, T. G., Day, R., Civelli, O., Douglass, J., Herbert, E., Akil, H., and Watson, S. J. (1988) J. Neurosci. 8, 3785-3796 [Abstract]
  18. van Tol, H. H. M., Voorhuis, D. T. A. M., and Burbach, J. P. H. (1987) Endocrinology 120, 71-76 [Abstract]
  19. Richard, S., and Zingg, H. H. (1991) Mol. Cell. Neurosci. 2, 501-510
  20. Burbach, J. P. H., Adan, R. A. H., van Tol, H. H. M., Verbeeck, M. A. E., Axelson, J. F., van Leeuwen, F., Beekman, J. M., and Geert, A. B. (1990) J. Neuroendocrinol. 2, 633-639
  21. Richard, S., and Zingg, H. H. (1990) J. Biol. Chem. 265, 6098-6103 [Abstract/Free Full Text]
  22. Adan, R. A. H., Cox, J. J., van Kats, J. P., and Burbach, J. P. H. (1992) J. Biol. Chem. 267, 3771-3777 [Abstract/Free Full Text]
  23. Richard, S., and Zingg, H. H. (1991) J. Biol. Chem. 266, 21428-21433 [Abstract/Free Full Text]
  24. Axelson, J. F., and van Leeuwen, F. W. (1990) J. Neuroendocrinol. 2, 209-267
  25. Lefebvre, D. L., Giaid, A., Bennett, H., Lariviere, R., and Zingg, H. H. (1992) Science 256, 1553-1555 [Medline] [Order article via Infotrieve]
  26. Lefebvre, D. L., Farookhi, R., Larcher, A., Neculcea, J., and Zingg, H. H. (1994) Endocrinology 134, 2556-2561 [Abstract]
  27. Lefebvre, D. L., Farookhi, R., Giaid, A., Neculcea, J., and Zingg, H. H. (1994) Endocrinology 134, 2562-2566 [Abstract]
  28. Adan, R. A. H., Walther, N., Cox, J. J., Ivell, R., and Burbach, J. P. H. (1991) Biochem. Biophys. Res. Commun. 175, 117-122 [Medline] [Order article via Infotrieve]
  29. Ruppert, S., Scherer, G., and Schutz, G. (1984) Nature 308, 554-557 [Medline] [Order article via Infotrieve]
  30. Ang, H.-L., Ungefroren, H., de Bree, F., Foo, N.-C., Carter, D. A., Burbach, J. P., Ivell, R., and Murphy, D. (1991) Endocrinology 128, 2110-2117 [Abstract]
  31. Ang, H.-L., Carter, D. A., and Murphy, D. (1993) EMBO J. 12, 2397-2409 [Abstract]
  32. Murphy, D., and Carter, D. A. (1993) Transgenic Techniques: Principles and Protocols , Humana Press, Totowa, NJ
  33. Zeng, Q., Carter, D. A., and Murphy, D. (1994) J. Neuroendocrinol. 6, 469-477 [Medline] [Order article via Infotrieve]
  34. Ivell, R., and Burbach, J. P. H. (1991) J. Neuroendocrinol. 3, 583-586
  35. Murphy, D., and Carter, D. A. (1992) Curr. Opin. Cell Biol. 4, 274-279 [Medline] [Order article via Infotrieve]
  36. Ang, H.-L., Ivell, R., Walther, N., Nicholson, H., Ungefroren, H., Millar, M., Carter, D. A., and Murphy, D. (1994) J. Endocrinol. 140, 53-62 [Abstract]
  37. Young, W. S., Reynolds, K., Shepard, E. A., Gainer, H., and Castel, M. (1990) J. Neuroendocrinol. 2, 917-925
  38. Belenky, M., Castel, M., Young, W. S., III, Gainer, H., and Cohen, S. (1992) Brain Res. 583, 279-286 [Medline] [Order article via Infotrieve]
  39. Gainer, H., and Wray, S. (1994) in The Physiology of Reproduction (Knobil, E., and Neill, J. D., eds) pp. 1099-1129, Raven Press, New York
  40. Ivell, R., Schmale, H., Krisch, B., Nahke, P., and Richter, D. (1986) EMBO J. 5, 971-977 [Abstract]

©1995 by The American Society for Biochemistry and Molecular Biology, Inc.